Kolexia
Fontenay Michaela
Biologie médicale
Hôpital Cochin
Paris, France
230 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Syndromes myélodysplasiques Leucémies Leucémie aigüe myéloïde COVID-19 Leucémie myélomonocytaire chronique Leucémie myéloïde Délétion de segment de chromosome Thrombose Thromboembolisme veineux

Industries

Celgene
3 collaboration(s)
Dernière en 2022
Leo Pharma
2 collaboration(s)
Dernière en 2022
BMS
1 collaboration(s)
Dernière en 2023
Sandoz
1 collaboration(s)
Dernière en 2020

Dernières activités

Along with PaO2/FiO2 ratio and lymphopenia, low HLA-DR monocytes are the only additional parameter that independently predicts the clinical course of undifferentiated SARS-CoV-2 patients in Emergency Departments.
Journal of leukocyte biology   15 février 2024
Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers.
Cell death & disease   14 février 2024
Enhanced fetal hematopoiesis in response to symptomatic SARS-CoV-2 infection during pregnancy.
Communications medicine   11 décembre 2023
Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023
Somatic Mutations and DNA Hypermethylation at Enhancers and Promoters Identify Distinct Subtypes within Lower-Risk Myelodysplastic Syndromes
65th ASH Annual Meeting Abstracts   02 novembre 2023
Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients
65th ASH Annual Meeting Abstracts   02 novembre 2023
Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications
65th ASH Annual Meeting Abstracts   02 novembre 2023
UBA1 Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes
65th ASH Annual Meeting Abstracts   02 novembre 2023
Impact of Mutational Burden and IPSS-M on Response to ESAs in Lower Risk Myelodysplastic Neoplasms
65th ASH Annual Meeting Abstracts   02 novembre 2023
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Essai Clinique (CHU Brest)   27 octobre 2023